Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 31;12(1):100. doi: 10.3390/cancers12010100

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Discovery and validation of the novel gene fusions in atypical TGCTs. A partial sequence chromatogram is shown from each fusion transcript, with the arrow depicting the fusion breakpoint. Gel electrophoresis images display respective cDNA fragment amplification. A positive band can be seen in Lane 1, supporting the presence of the fusion product. M, DNA marker (Promega, Madison, WI, USA); Lane 1, patient case; Lane 2, HapMap normal RNA control; Lane 3, no template control (water control). (A,B) Identification and validation of NIPBL-ERG fusion transcript by anchored multiple PCR (AMP), Sanger sequencing, and RT-PCR. (C) ERG overexpression in the mononuclear tumor cells by immunohistochemistry (IHC). Identification and validation of FN1-ROS1 (D,E) and YAP1-MAML2 (F,G) fusion transcripts by AMP, Sanger sequencing, and RT-PCR.

Discovery and validation of the novel gene fusions in atypical TGCTs. A partial sequence chromatogram is shown from each fusion transcript, with the arrow depicting the fusion breakpoint. Gel electrophoresis images display respective cDNA fragment amplification. A positive band can be seen in Lane 1, supporting the presence of the fusion product. M, DNA marker (Promega, Madison, WI, USA); Lane 1, patient case; Lane 2, HapMap normal RNA control; Lane 3, no template control (water control). (A,B) Identification and validation of NIPBL-ERG fusion transcript by anchored multiple PCR (AMP), Sanger sequencing, and RT-PCR. (C) ERG overexpression in the mononuclear tumor cells by immunohistochemistry (IHC). Identification and validation of FN1-ROS1 (D,E) and YAP1-MAML2 (F,G) fusion transcripts by AMP, Sanger sequencing, and RT-PCR.